Andrew Bayliffe

Andrew Bayliffe

Corporate Officer/Principal chez Marengo Therapeutics, Inc.

Consumer Services
Health Technology
Finance

Profil

Andrew Bayliffe is chief scientific officer at Marengo Therapeutics and a venture partner at ATP.
With more than 20 years of leadership experience in the biopharmaceutical industry, he possesses expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas.
Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery unit at GSK’s R&D headquarters in Stevenage, UK, and held senior roles in antibody discovery and development in the US and UK.
Andrew is an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast.
He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.

Postes actifs de Andrew Bayliffe

SociétésPosteDébut
Corporate Officer/Principal 01/01/2021
Private Equity Investor 01/10/2019
Tous les postes actifs de Andrew Bayliffe

Formation de Andrew Bayliffe

University of Leeds Doctorate Degree
Manchester Metropolitan University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Andrew Bayliffe

Relations

53

Relations au 1er degré

4

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées2

Health Technology

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Andrew Bayliffe
-40% Prolongation exceptionnelle : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT